GlassScriptPhysician profile
John T Hsieh
NPI 1659376606
$5,514.10
in general payments reported to CMS, 2019-2025
26 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $437 · 2021: $516 · 2022: $1,234 · 2023: $626 · 2024: $923 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,634 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.29 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $788.68 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $499.82 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $478.85 | 2019-2025 | Jynarque |
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 | |
| Amgen INC. | $386.87 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $335.07 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $328.63 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.62 | 2022-2025 | Jardiance |
| Horizon Therapeutics Plc | $233.01 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $227.50 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $221.16 | 2019-2025 | Vafseo |
| Travere Therapeutics, INC. | $201.82 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $192.51 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $181.30 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $147.88 | 2020-2025 | Benlysta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $130.60 | 2024-2025 | |
| Vyaire Medical, INC. | $119.74 | 2022 | |
| Mallinckrodt Hospital Products INC. | $109.32 | 2022-2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $76.12 | 2019-2023 | |
| Fresenius USA Marketing, INC. | $50.64 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $27.32 | 2025 | Empaveli |
| Masimo Corporation | $26.50 | 2022 | |
| Chiesi USA, INC. | $23.44 | 2019 | |
| Novo Nordisk INC | $22.18 | 2024 | |
| Abbvie INC. | $17.90 | 2019 | |
| Scpharmaceuticals INC. | $15.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hsieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.